1. In vitro antiviral treatment of BDV-infected human oligodendroglia cells.
In vitro antiviral treatment of BDV-infected human oligodendroglia cells. Persistently infected oligodendroglia cells were split every 3 days and maintained in medium containing amantadine (0.4 μg/ml, therapeutic blood level doses). At the indicated time points, infectivity in these cells was titered on young rabbit brain cells (for details, see reference 7). Note the time-dependent infectivity decrease for the sensitive wild-type strains, two human isolates (Hu-H1 [8] and Hu-HUSA1, isolated from an American chronic fatigue syndrome patient [9]), and one equine isolate (Equ-Cres, isolated from PBMCs of a horse with Borna disease) versus stable titers in two resistant laboratory strains (strains V and Dessau).
Liv Bode, and Hans Ludwig Clin. Microbiol. Rev. 2003; doi: /CMR